MUC1 is an oncoprotein with a significant role in apoptosis (Review)
- Authors:
- Katarzyna Supruniuk
- Iwona Radziejewska
-
Affiliations: Department of Medical Chemistry, Medical University of Białystok, 15‑222 Białystok, Poland - Published online on: July 15, 2021 https://doi.org/10.3892/ijo.2021.5248
- Article Number: 68
-
Copyright: © Supruniuk et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Behera SK, Praharaj AB, Dehury B and Negi S: Exploring the role and diversity of mucins in health and disease with special insight into non-communicable diseases. Glyconconj J. 32:575–613. 2015. View Article : Google Scholar | |
|
Dhanisha SS, Guruvayoorappan C, Drishya S and Abeesh P: Mucins: Structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets. Crit Rev Oncol Hematol. 122:98–122. 2018. View Article : Google Scholar | |
|
Cornick S, Tawiah A and Chadee K: Roles and regulation of the mucus barrier in the gut. Tissue Barriers. 3:e9824262015. View Article : Google Scholar | |
|
Moniaux N, Escande F, Porchet N, Aubert JP and Batra SK: Structural organization and classification of the human mucin genes. Front Biosci. 6:D1192–D1206. 2001. View Article : Google Scholar | |
|
Nath S and Mukherjee P: MUC1: A multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 20:332–342. 2014. View Article : Google Scholar | |
|
Hanson RL and Hollingsworth MA: Functional consequences of differential O-glycosylation of MUC1, MUC4, and MUC16 (downstream effects on signaling). Biomolecules. 6:342016. View Article : Google Scholar | |
|
Jonckheere N and Van Seuningen I: The membrane-bound mucins: How large O-glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene-based and immunotherapies. Crit Rev Oncog. 14:177–196. 2008. View Article : Google Scholar | |
|
Lau SK, Weiss LM and Chu PG: Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: An immunohistochemical study. Am J Clin Pathol. 122:61–69. 2004. View Article : Google Scholar | |
|
Reynolds IS, Fichtner M, McNamara DA, Kay EW, Prehn JHM and Burke JP: Mucin glycoproteins block apoptosis; promote invasion, proliferation, and migration; and cause chemoresistance through diverse pathways in epithelial cancers. Cancer Metastasis Rev. 38:237–257. 2019. View Article : Google Scholar | |
|
Altschuler Y, Kinlough CL, Poland PA, Bruns JB, Apodaca G, Weisz OA and Hughey RP: Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol Biol Cell. 11:819–831. 2000. View Article : Google Scholar | |
|
Katoch B, Sebastian S, Sahdev S, Padh H, Hasnain SE and Begum R: Programmed cell death and its clinical implications. Indian J Exp Biol. 40:513–524. 2002. | |
|
Elmore S: Apoptosis: A review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar | |
|
D'Arcy MS: Cell death: A review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 43:582–592. 2019. View Article : Google Scholar | |
|
Wong RS: Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011. View Article : Google Scholar | |
|
Jan R and Chaudhry GE: Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv Pharm Bull. 9:205–218. 2019. View Article : Google Scholar | |
|
Papaliagkas V, Anogianaki A, Anogianakis G and Ilonidis G: The proteins and the mechanisms of apoptosis: A mini-review of the fundamentals. Hippokratia. 11:108–113. 2007. | |
|
Taylor R, Cullen S and Martin S: Apoptosis: Controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 9:231–241. 2008. View Article : Google Scholar | |
|
Shakeri R, Kheirollahi A and Davoodi J: Apaf-1: Regulation and function in cell death. Biochimie. 135:111–125. 2017. View Article : Google Scholar | |
|
Shimizu S, Narita M and Tsujimoto Y: Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 399:483–487. 1999. View Article : Google Scholar | |
|
Savitskaya MA and Onishchenko GE: Mechanisms of apoptosis. Biochemistry (Mosc). 80:1393–1405. 2015. View Article : Google Scholar | |
|
O'Brien MA and Kirby R: Apoptosis: A review of pro-apoptotic and anti-apoptotic pathways and dysregulation in disease. J Vet Emerg Crit Care (San Antonio). 18:572–585. 2008. View Article : Google Scholar | |
|
Julien O and Wells JA: Caspases and their substrates. Cell Death Differ. 24:1380–1389. 2017. View Article : Google Scholar | |
|
Porter AG and Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999. View Article : Google Scholar | |
|
Van Ba H and Hwang I: Role of caspase-9 in the effector caspases and genome expressions, and growth of bovine skeletal myoblasts. Dev Growth Differ. 56:131–142. 2014. View Article : Google Scholar | |
|
Dempsey PW, Doyle SE, He JQ and Cheng G: The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 14:193–209. 2003. View Article : Google Scholar | |
|
Srivastava RK: TRAIL/Apo-2L: Mechanisms and clinical applications in cancer. Neoplasia. 3:535–546. 2001. View Article : Google Scholar | |
|
Li H, Zhu H, Xu CJ and Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 94:491–501. 1998. View Article : Google Scholar | |
|
Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 94:481–490. 1998. View Article : Google Scholar | |
|
Valentijn AJ and Gilmore AP: Translocation of full-length Bid to mitochondria during anoikis. J Biol Chem. 279:32848–32857. 2004. View Article : Google Scholar | |
|
Woods NT, Yamaguchi H, Lee FY, Bhalla KN and Wang HG: Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res. 67:10744–10752. 2007. View Article : Google Scholar | |
|
Zhao Q, Piyush T, Chen C, Hollingsworth MA, Hilkens J, Rhodes JM and Yu LG: MUC1 extracellular domain confers resistance of epithelial cancer cells to anoikis. Cell Death Dis. 5:e14382014. View Article : Google Scholar | |
|
Kim YN, Koo KH, Sung JY, Yun UJ and Kim H: Anoikis resistance: An essential prerequisite for tumor metastasis. Int J Cell Biol. 2012:3068792012. View Article : Google Scholar | |
|
Paoli P, Giannoni E and Chiarugi P: Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta. 1833:3481–3498. 2013. View Article : Google Scholar | |
|
Yang MC, Lin RW, Huang SB, Huang SY, Chen WJ, Wang S, Hong YR and Wang C: Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53. Cell Cycle. 15:394–402. 2016. View Article : Google Scholar | |
|
Aoudjit F and Vuori K: Matrix attachment regulates Fas-induced apoptosis in endothelial cells: A role for c-flip and implications for anoikis. J Cell Biol. 152:633–643. 2001. View Article : Google Scholar | |
|
Marconi A, Atzei P, Panza C, Fila C, Tiberio R, Truzzi F, Wachter T, Leverkus M and Pincelli C: FLICE/caspase-8 activation triggers anoikis induced by beta1-integrin blockade in human keratinocytes. J Cell Sci. 117:5815–5823. 2004. View Article : Google Scholar | |
|
Hattrup CL and Gendler SJ: Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 70:431–457. 2008. View Article : Google Scholar | |
|
Singh PK and Hollingsworth MA: Cell surface-associated mucins in signal transduction. Trends Cell Biol. 16:467–476. 2006. View Article : Google Scholar | |
|
Hagiwara M, Yasumizu Y, Yamashita N, Rajabi H, Fushimi A, Long MD, Li W, Bhattacharya A, Ahmad R, Oya M, et al: MUC1-C Activates the BAF (mSWI/SNF) complex in prostate cancer stem cells. Cancer Res. 81:1111–1122. 2021. View Article : Google Scholar | |
|
Hanson JM, BroweIl DA, Cunliffe WJ, Varma J, Allen A, Hemming D, Shenton BK, Young JR, Higgs MJ, Brotherick I and Pearson JP: MUC1 expression in primary breast cancer: The effect of tamoxifen treatment. Breast Cancer Res Treat. 67:215–222. 2001. View Article : Google Scholar | |
|
Kufe DW: Mucins in cancer: Function, prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar | |
|
Raina D, Ahmad R, Rajabi H, Panchamoorthy G, Kharbanda S and Kufe D: Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. Int J Oncol. 40:1643–1649. 2012. | |
|
Yang J: Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer. Med Oncol. 37:342020. View Article : Google Scholar | |
|
Apostolopoulos V, Stojanovska L and Gargosky SE: MUC1 (CD227): A multi-tasked molecule. Cell Mol Life Sci. 72:4475–4500. 2015. View Article : Google Scholar | |
|
Taylor-Papadimitriou J: Report on the first international workshop on carcinoma-associated mucins. Int J Cancer. 49:1–5. 1991. View Article : Google Scholar | |
|
Gendler SJ and Spicer AP: Epithelial mucin genes. Annu Rev Physiol. 57:607–634. 1995. View Article : Google Scholar | |
|
Hanisch FG and Müller S: MUC1: The polymorphic appearance of a human mucin. Glycobiology. 10:439–449. 2000. View Article : Google Scholar | |
|
Agrawal B, Krantz MJ, Parker J and Longenecker BM: Expression of MUC1 mucin on activated human T cells: Implications for a role of MUC1 in normal immune regulation. Cancer Res. 58:4079–4081. 1998. | |
|
Dent GA, Civalier CJ, Brecher ME and Bentley SA: MUC1 expression in hematopoietic tissues. Am J Clin Pathol. 111:741–747. 1999. View Article : Google Scholar | |
|
Franke FE, Kraus S, Eiermann C, Pauls K, Lalani EN and Bergmann M: MUC1 in normal and impaired spermatogenesis. Mol Hum Reprod. 7:505–512. 2001. View Article : Google Scholar | |
|
Seo JT, Lee JS, Jun JH and Yang MH: Expression of mucin genes in the human testis and its relationship to spermatogenesis. Yonsei Med J. 46:667–672. 2005. View Article : Google Scholar | |
|
Cascio S and Finn OJ: Intra- and extra-cellular events related to altered glycosylation of MUC1 promote chronic inflammation, tumor progression, invasion, and metastasis. Biomolecules. 6:392016. View Article : Google Scholar | |
|
Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA and Tabak LA: Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 22:736–756. 2012. View Article : Google Scholar | |
|
Taherali F, Varum F and Basit AW: A slippery slope: On the origin, role and physiology of mucus. Adv Drug Deliv Rev. 124:16–33. 2018. View Article : Google Scholar | |
|
Raina D, Agarwal P, Lee J, Bharti A, McKnight CJ, Sharma P, Kharbanda S and Kufe D: Characterization of the MUC1-C cytoplasmic domain as a cancer target. PLoS One. 10:e01351562015. View Article : Google Scholar | |
|
McAuley JL, Corcilius L, Tan HX, Payne RJ, McGuckin MA and Brown LE: The cell surface mucin MUC1 limits the severity of influenza A virus infection. Mucosal Immunol. 10:1581–1593. 2017. View Article : Google Scholar | |
|
Thathiah A, Blobel CP and Carson DD: Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding. J Biol Chem. 278:3386–3394. 2003. View Article : Google Scholar | |
|
Tarp MA and Clausen H: Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta. 1780:546–563. 2008. View Article : Google Scholar | |
|
Awaya H, Takeshima Y, Yamasaki M and Inai K: Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am J Clin Pathol. 121:644–653. 2004. View Article : Google Scholar | |
|
Horm TM and Schroeder JA: MUC1 and metastatic cancer: Expression, function and therapeutic targeting. Cell Adh Migr. 7:187–198. 2013. View Article : Google Scholar | |
|
Krishn SR, Kaur S, Smith LM, Johansson SL, Jain M, Patel A, Gautam SK, Hollingsworth MA, Mandel U, Clausen H, et al: Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer. Cancer Lett. 374:304–314. 2016. View Article : Google Scholar | |
|
Singh AP, Chauhan SC, Bafna S, Johansson SL, Smith LM, Moniaux N, Lin MF and Batra SK: Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Prostate. 66:421–429. 2006. View Article : Google Scholar | |
|
Gao Y, Liu Z, Feng J, Sun Q, Zhang B, Zheng W and Ma W: Expression pattern of polypeptide N-acetylgalactosaminyltransferase-10 in gastric carcinoma. Oncol Lett. 5:113–116. 2013. View Article : Google Scholar | |
|
Guda K, Moinova H, He J, Jamison O, Ravi L, Natale L, Lutterbaugh J, Lawrence E, Lewis S, Willson JK, et al: Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers. Proc Natl Acad Sci USA. 106:12921–12925. 2009. View Article : Google Scholar | |
|
Stowell SR, Ju T and Cummings RD: Protein glycosylation in cancer. Annu Rev Pathol. 10:473–510. 2015. View Article : Google Scholar | |
|
Liesche F, Kölbl AC, Ilmer M, Hutter S, Jeschke U and Andergassen U: Role of N-acetylgalactosaminyltransferase 6 in early tumorigenesis and formation of metastasis. Mol Med Rep. 13:4309–4314. 2016. View Article : Google Scholar | |
|
Hakomori S: Aberrant glycosylation in cancer cell membranes as focused on glycolipids: Overview and perspectives. Cancer Res. 45:2405–2414. 1985. | |
|
Radziejewska I, Supruniuk K, Nazaruk J, Karna E, Popławska B, Bielawska A and Galicka A: Rosmarinic acid influences collagen, MMPs, TIMPs, glycosylation and MUC1 in CRL-1739 gastric cancer cell line. Biomed Pharmacother. 107:397–407. 2018. View Article : Google Scholar | |
|
Syrkina MS, Maslakova AA, Potashnikova DM, Veiko VP, Vassetzky YS and Rubtsov MA: Dual role of the extracellular domain of human mucin MUC1 in metastasis. J Cell Biochem. 118:4002–4011. 2017. View Article : Google Scholar | |
|
Ho WL, Hsu WM, Huang MC, Kadomatsu K and Nakagawara A: Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma. J Hematol Oncol. 9:1002016. View Article : Google Scholar | |
|
Liu B, Pan S, Xiao Y, Liu Q, Xu J and Jia L: LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway. J Exp Clin Cancer Res. 37:3162018. View Article : Google Scholar | |
|
Mao Y, Zhang Y, Fan S, Chen L, Tang L, Chen X and Lyu J: GALNT6 promotes tumorigenicity and metastasis of breast cancer cell via β-catenin/MUC1-C signaling pathway. Int J Biol Sci. 15:169–182. 2019. View Article : Google Scholar | |
|
Bäckström M, Thomsson KA, Karlsson H and Hansson GC: Sensitive liquid chromatography-electrospray mass spectrometry allows for the analysis of the O-glycosylation of immunoprecipitated proteins from cells or tissues: Application to MUC1 glycosylation in cancer. J Proteome Res. 8:538–545. 2009. View Article : Google Scholar | |
|
Blanas A, Sahasrabudhe NM, Rodríguez E, van Kooyk Y and van Vliet SJ: Fucosylated antigens in cancer: An alliance toward tumor progression, metastasis, and resistance to chemotherapy. Front Oncol. 8:392018. View Article : Google Scholar | |
|
Jia L, Zhang J, Ma T, Guo Y, Yu Y and Cui J: The Function of Fucosylation in Progression of Lung Cancer. Front Oncol. 8:5652018. View Article : Google Scholar | |
|
Chen Z, Gulzar ZG, St Hill CA, Walcheck B and Brooks JD: Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers. Prostate. 74:1059–1067. 2014. View Article : Google Scholar | |
|
Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, Kabuto T, Iwanaga T, Matsushita Y and Irimura T: Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: Clinicopathological and immunohistochemical study. Cancer Res. 53:3632–3637. 1993. | |
|
Ricardo S, Marcos-Silva L, Valente C, Coelho R, Gomes R and David L: Mucins MUC16 and MUC1 are major carriers of SLe(a) and SLe(x) in borderline and malignant serous ovarian tumors. Virchows Arch. 468:715–722. 2016. View Article : Google Scholar | |
|
Mori Y, Akita K, Yashiro M, Sawada T, Hirakawa K, Murata T and Nakada H: Binding of galectin-3, a β-galactoside-binding lectin, to MUC1 protein enhances phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt, promoting tumor cell malignancy. J Biol Chem. 290:26125–26140. 2015. View Article : Google Scholar | |
|
Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S and Kufe D: The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell. 27:992–1004. 2007. View Article : Google Scholar | |
|
Sciacchitano S, Lavra L, Morgante A, Ulivieri A, Magi F, De Francesco GP, Bellotti C, Salehi LB and Ricci A: Galectin-3: One molecule for an alphabet of diseases, from A to Z. Int J Mol Sci. 19:3792018. View Article : Google Scholar | |
|
Zhao Q, Guo X, Nash GB, Stone PC, Hilkens J, Rhodes JM and Yu LG: Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res. 69:6799–6806. 2009. View Article : Google Scholar | |
|
Kufe DW: MUC1-C oncoprotein as a target in breast cancer: Activation of signaling pathways and therapeutic approaches. Oncogene. 32:1073–1081. 2013. View Article : Google Scholar | |
|
Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S and Kufe D: Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 5:163–175. 2004. View Article : Google Scholar | |
|
Yin L and Kufe D: Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem. 278:35458–35464. 2003. View Article : Google Scholar | |
|
Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest. 107:241–246. 2001. View Article : Google Scholar | |
|
Dyomin VG, Palanisamy N, Lloyd KO, Dyomina K, Jhanwar SC, Houldsworth J and Chaganti RS: MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood. 95:2666–2671. 2000. View Article : Google Scholar | |
|
Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr and Sledge GW Jr: Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol. 17:3629–3639. 1997. View Article : Google Scholar | |
|
Stroopinsky D, Rosenblatt J, Ito K, Mills H, Yin L, Rajabi H, Vasir B, Kufe T, Luptakova K, Arnason J, et al: MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res. 73:5569–5579. 2013. View Article : Google Scholar | |
|
Li Y, Yu WH, Ren J, Huang L, Kharbanda S, Loda M and Kufe D: Heregulin targets γ-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 protein. Mol Cancer Res. 1:765–775. 2003. | |
|
Agata N, Ahmad R, Kawano T, Raina D, Kharbanda S and Kufe D: MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8. Cancer Res. 68:6136–6144. 2008. View Article : Google Scholar | |
|
Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S and Kufe D: MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaBsignalling. Nat Cell Biol. 9:1419–1427. 2007. View Article : Google Scholar | |
|
Escher TE, Lui AJ, Geanes ES, Walter KR, Tawfik O, Hagan CR and Lewis-Wambi J: Interaction between MUC1 and STAT1 drives IFITM1 overexpression in aromatase inhibitor-resistant breast cancer cells and mediates estrogen-induced apoptosis. Mol Cancer Res. 17:1180–1194. 2019. View Article : Google Scholar | |
|
Pistritto G, Trisciuoglio D, Ceci C, Garufi A and D'Orazi G: Apoptosis as anticancer mechanism: Function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 8:603–619. 2016. View Article : Google Scholar | |
|
Comalada M, Xaus J, Valledor AF, López-López C, Pennington DJ and Celada A: PKC epsilon is involved in JNK activation that mediates LPS-induced TNF-alpha, which induces apoptosis in macrophages. Am J Physiol Cell Physiol. 285:C1235–1245. 2003. View Article : Google Scholar | |
|
Rajabi H and Kufe D: MUC1-C oncoprotein integrates a program of EMT, epigenetic reprogramming and immune evasion in human carcinomas. Biochim Biophys Acta Rev Cancer. 1868:117–122. 2017. View Article : Google Scholar | |
|
Rajabi H, Hiraki M and Kufe D: MUC1-C activates polycomb complexes and downregulates tumor suppressor genes in human cancer cells. Oncogene. 37:2079–2088. 2018. View Article : Google Scholar | |
|
Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and Korsmeyer SJ: Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science. 292:727–730. 2001. View Article : Google Scholar | |
|
Westphal D, Dewson G, Czabotar PE and Kluck RM: Molecular biology of Bax and Bak activation and action. Biochim Biophys Acta. 1813:521–531. 2011. View Article : Google Scholar | |
|
Peña-Blanco A and García-Sáez AJ: Bax, Bak and beyond - mitochondrial performance in apoptosis. FEBS J. 285:416–431. 2018. View Article : Google Scholar | |
|
Ahmad R, Alam M, Rajabi H and Kufe D: The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function. J Biol Chem. 287:20866–20875. 2012. View Article : Google Scholar | |
|
D'Alessio M, De Nicola M, Coppola S, Gualandi G, Pugliese L, Cerella C, Cristofanon S, Civitareale P, Ciriolo MR, Bergamaschi A, et al: Oxidative Bax dimerization promotes its translocation to mitochondria independently of apoptosis. FASEB J. 19:1504–1506. 2005. View Article : Google Scholar | |
|
Leng Y, Cao C, Ren J, Huang L, Chen D, Ito M and Kufe D: Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem. 282:19321–19330. 2007. View Article : Google Scholar | |
|
Cangul H, Broday L, Salnikow K, Sutherland J, Peng W, Zhang Q, Poltaratsky V, Yee H, Zoroddu MA and Costa M: Molecular mechanisms of nickel carcinogenesis. Toxicol Lett. 127:69–75. 2002. View Article : Google Scholar | |
|
Lu H, Shi X, Costa M and Huang C: Carcinogenic effect of nickel compounds. Mol Cell Biochem. 279:45–67. 2005. View Article : Google Scholar | |
|
Castorina A and Giunta S: Mucin 1 (MUC1) signalling contributes to increase the resistance to cell death in human bronchial epithelial cells exposed to nickel acetate. Biometals. 27:1149–1158. 2014. View Article : Google Scholar | |
|
Schroeder JA, Masri AA, Adriance MC, Tessier JC, Kotlarczyk KL, Thompson MC and Gendler SJ: MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene. 23:5739–5747. 2004. View Article : Google Scholar | |
|
Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro GI, Supko J, Kharbanda S and Kufe D: Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther. 10:806–816. 2011. View Article : Google Scholar | |
|
Andjelic S, Hsia C, Suzuki H, Kadowaki T, Koyasu S and Liou HC: Phosphatidylinositol 3-kinase and NF-kappa B/Rel are at the divergence of CD40-mediated proliferation and survival pathways. J Immunol. 165:3860–3867. 2000. View Article : Google Scholar | |
|
Ahmad R, Raina D, Joshi MD, Kawano T, Ren J, Kharbanda S and Kufe D: MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer Res. 69:7013–7021. 2009. View Article : Google Scholar | |
|
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:231–241. 1997. View Article : Google Scholar | |
|
Datta SR, Katsov A, Hu L, Petros A, Fesik SW, Yaffe MB and Greenberg ME: 143-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell. 6:41–51. 2000. View Article : Google Scholar | |
|
Fleury C, Mignotte B and Vayssière JL: Mitochondrial reactive oxygen species in cell death signaling. Biochimie. 84:131–141. 2002. View Article : Google Scholar | |
|
Redza-Dutordoir M and Averill-Bates DA: Activation of apoptosis signalling pathways by reactive oxygen species. Biochim Biophys Acta. 1863:2977–2992. 2016. View Article : Google Scholar | |
|
Yin L, Huang L and Kufe D: MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem. 279:45721–45727. 2004. View Article : Google Scholar | |
|
Park JA, Park S, Choi JK, Han MK and Lee Y: Inhibition of MUC1-C Increases ROS and Cell Death in Mouse Embryonic Stem Cells. Int J Stem Cells. 14:180–190. 2021. | |
|
Liu Y, Ao X, Ding W, Ponnusamy M, Wu W, Hao X, Yu W, Wang Y, Li P and Wang J: Critical role of FOXO3a in carcinogenesis. Mol Cancer. 17:1042018. View Article : Google Scholar | |
|
Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature. 351:453–456. 1991. View Article : Google Scholar | |
|
Amaral JD, Xavier JM, Steer CJ and Rodrigues CM: The role of p53 in apoptosis. Discov Med. 9:145–152. 2010. | |
|
Wei X, Xu H and Kufe D: Human MUC1 oncoprotein regulates p53 responsive gene transcription in the genotoxic stress response. Cancer Cell. 7:167–178. 2005. View Article : Google Scholar | |
|
Huang HZ, Yin YF, Wan WJ, Xia D, Wang R and Shen XM: Up-regulation of microRNA-136 induces apoptosis and radiosensitivity of esophageal squamous cell carcinoma cells by inhibiting the expression of MUC1. Exp Mol Pathol. 110:1042782019. View Article : Google Scholar | |
|
Wang JJ, Li ZF, Li XJ, Han Z, Zhang L and Liu ZJ: Effects of microRNA-136 on melanoma cell proliferation, apoptosis, and epithelial-mesenchymal transition by targetting PMEL through the Wnt signaling pathway. Biosci Rep. 37:BSR201707432017. View Article : Google Scholar | |
|
Wang L, Wu X, Wang B, Wang Q and Han L: Mechanisms of miR-145 regulating invasion and metastasis of ovarian carcinoma. Am J Transl Res. 9:3443–3451. 2017. | |
|
Wang X, Zhou X, Zeng F, Wu X and Li H: miR-485-5p inhibits the progression of breast cancer cells by negatively regulating MUC1. Breast Cancer. 27:765–775. 2020. View Article : Google Scholar | |
|
Du C, Fang M, Li Y, Li L and Wang X: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 102:33–42. 2000. View Article : Google Scholar | |
|
Tummers B and Green DR: Caspase-8: Regulating life and death. Immunol Rev. 277:76–89. 2017. View Article : Google Scholar | |
|
Ren J, Raina D, Chen W, Li G, Huang L and Kufe D: MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res. 4:873–883. 2006. View Article : Google Scholar | |
|
Chen Q, Li D, Ren J, Li C and Xiao ZX: MUC1 activates JNK1 and inhibits apoptosis under genotoxic stress. Biochem Biophys Res Commun. 440:179–183. 2013. View Article : Google Scholar | |
|
Dunn C, Wiltshire C, MacLaren A and Gillespie DA: Molecular mechanism and biological functions of c-Jun N-terminal kinase signalling via the c-Jun transcription factor. Cell Signal. 14:585–593. 2002. View Article : Google Scholar | |
|
Yarza R, Vela S, Solas M and Ramirez MJ: c-Jun N-terminal Kinase (JNK) signaling as a therapeutic target for Alzheimer's disease. Front Pharmacol. 6:3212016. View Article : Google Scholar | |
|
Zhang AM, Chi XH, Bo ZQ, Huang XF and Zhang J: MUC1 gene silencing inhibits proliferation, invasion, and migration while promoting apoptosis of oral squamous cell carcinoma cells. Biosci Rep. 39:BSR201821932019. View Article : Google Scholar | |
|
Tanaka Y, Terai Y, Kawaguchi H, Fujiwara S, Yoo S, Tsunetoh S, Takai M, Kanemura M, Tanabe A and Ohmichi M: Prognostic impact of EMT (epithelial-mesenchymal-transition)-related protein expression in endometrial cancer. Cancer Biol Ther. 14:13–19. 2013. View Article : Google Scholar | |
|
Vega S, Morales AV, Ocaña OH, Valdés F, Fabregat I and Nieto MA: Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 18:1131–1143. 2004. View Article : Google Scholar | |
|
Renauld JC: Class II cytokine receptors and their ligands: Key antiviral and inflammatory modulators. Nat Rev Immunol. 3:667–676. 2003. View Article : Google Scholar | |
|
Yi FT and Lu QP: Mucin 1 promotes radioresistance in hepatocellular carcinoma cells through activation of JAK2/STAT3 signaling. Oncol Lett. 14:7571–7576. 2017. | |
|
Kato K, Lillehoj EP and Kim KC: MUC1 regulates epithelial inflammation and apoptosis by PolyI:C through inhibition of Toll/IL-1 receptor-domain-containing adapter-inducing IFN-β (TRIF) recruitment to Toll-like receptor 3. Am J Respir Cell Mol Biol. 51:446–454. 2014. View Article : Google Scholar | |
|
Tréhoux S, Duchêne B, Jonckheere N and Van Seuningen I: The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways. Biochem Biophys Res Commun. 456:757–762. 2015. View Article : Google Scholar | |
|
Xu X, Wells A, Padilla MT, Kato K, Kim KC and Lin Y: A signaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance. Carcinogenesis. 35:2457–2466. 2014. View Article : Google Scholar | |
|
Frisch SM and Ruoslahti E: Integrins and anoikis. Curr Opin Cell Biol. 9:701–706. 1997. View Article : Google Scholar | |
|
Piyush T, Rhodes JM and Yu LG: MUC1 O-glycosylation contributes to anoikis resistance in epithelial cancer cells. Cell Death Discov. 3:170442017. View Article : Google Scholar |
